Stockscreener 앱 받기
2.67
0.37%
-0.01
Galectin Therapeutics Inc 주식(GALT)의 최신 뉴스
Galectin Therapeutics (GALT) Receives Buy Rating: How Will This Impact the Shares? - Bitget
Galectin Therapeutics (GALT) upgraded to buy: What does it mean for the stock? - MSN
Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
HC Wainwright Boosts FY2026 Earnings Estimate for Galectin Therapeutics - National Today
FY2026 Earnings Estimate for GALT Issued By HC Wainwright - MarketBeat
Aug PostEarnings: Can Galectin Therapeutics Inc reach all time highs this year2026 Trading Recap & Verified Swing Trading Watchlist - baoquankhu1.vn
What is HC Wainwright's Estimate for GALT Q1 Earnings? - MarketBeat
Galectin Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Galectin Therapeutics (NASDAQ: GALT) launches $32.5M ATM; 3% agent fee - Stock Titan
Galectin Therapeutics Reports 2025 Financial Results, Advances Belapectin Program for MASH Cirrhosis, and Extends Cash Runway Through 2027 - Minichart
Galectin Therapeutics Reports 2025 Financial Results - National Today
Galectin Therapeutics Inc. (GALT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Galectin Therapeutics 2025 Annual Report: Clinical Trials, Regulatory Challenges, and Biopharma Industry Risks - Minichart
Galectin Therapeutics (NASDAQ:GALT) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Liver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costs - TradingView
With no approved MASH cirrhosis drugs, Galectin takes belapectin to FDA - Stock Titan
NAVIGATE MASH data and funding risks at Galectin (NASDAQ: GALT) - Stock Titan
Belapectin data and $30.8M 2025 loss at Galectin (NASDAQ: GALT) - Stock Titan
Galectin Therapeutics 10-K: R&D cuts reduce cash burn; cash runway to Apr 2027 - TradingView
Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
What makes Galectin Therapeutics Inc stock attractive today2026 Trade Ideas & Low Risk High Win Rate Picks - baoquankhu1.vn
Galectin Therapeutics Short Interest Rises 27% in March - National Today
Galectin Therapeutics Inc. (NASDAQ:GALT) Short Interest Up 27.0% in March - MarketBeat
Risk Recap: Is Galectin Therapeutics Inc in a bullish channel2026 Historical Comparison & Risk Managed Investment Entry Signals - baoquankhu1.vn
Retail Trends: Is Galectin Therapeutics Inc gaining market share2026 Growth vs Value & Weekly Top Gainers Alerts - baoquankhu1.vn
Galectin Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Financial Analysis: Galectin Therapeutics (NASDAQ:GALT) & Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Aug Gainers: Does Galectin Therapeutics Inc stock have upside surprise potential2026 Selloffs & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Galectin Therapeutics (FRA:PHPN) PB Ratio : (As of Mar. 25, 2026) - gurufocus.com
Galectin Therapeutics (GALT) Projected to Post Earnings on Monday - Defense World
Wall Street Recap: What makes Galectin Therapeutics Inc stock attractive today - baoquankhu1.vn
Galectin Therapeutics Stock (ISIN: US3631621074) Faces Investor Scrutiny Amid Legal Probe and Earnin - AD HOC NEWS
Galectin Therapeutics Adds Neurosurgeon Henry Brem to Board - The Globe and Mail
Galectin Therapeutics Highlights Belapectin Data in MASH Cirrhosis KOL Event, Eyes Next Steps - Defense World
Galectin Therapeutics Appoints Dr. Henry Brem to Board, Advancing Belapectin for MASH Cirrhosis and Cancer Therapies - Minichart
Galectin Therapeutics appoints Johns Hopkins neurosurgeon to board By Investing.com - Investing.com India
Galectin Therapeutics Inc. Appoints Henry Brem, M.D. as Independent Director to Board of Directors - marketscreener.com
Sentiment Recap: Is Galectin Therapeutics Inc forming a double bottom2026 Trade Ideas & Consistent Growth Equity Picks - baoquankhu1.vn
Galectin Therapeutics appoints Johns Hopkins neurosurgeon to board - Investing.com
Galectin Therapeutics (GALT) director awarded 60,000 stock options at $3.1600 - Stock Titan
Director Henry Brem joins Galectin (GALT) board and reports zero share ownership - Stock Titan
Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D. - Bitget
Henry Brem, M.D. joins Galectin Therapeutics (GALT) Board as independent director - Stock Titan
Portfolio Shifts: Whats the outlook for Galectin Therapeutics Incs sectorTake Profit & Accurate Entry/Exit Alerts - baoquankhu1.vn
Recap Report: Is Galectin Therapeutics Inc forming a double bottomQuarterly Market Summary & Accurate Technical Buy Alerts - baoquankhu1.vn
Take Profit: Does Galectin Therapeutics Inc have a sustainable dividendJuly 2025 Market Mood & Detailed Earnings Play Strategies - baoquankhu1.vn
Panic Selling: Will Galectin Therapeutics Inc outperform its industry peers2025 Price Momentum & Weekly Stock Breakout Alerts - baoquankhu1.vn
Highs Report: Is Galectin Therapeutics Inc forming a double bottomJuly 2025 Selloffs & Weekly Chart Analysis and Guides - baoquankhu1.vn
Buyout Rumor: Can Galectin Therapeutics Inc weather a recessionJuly 2025 Summary & Reliable Intraday Trade Alerts - baoquankhu1.vn
GALT Should I Buy - Intellectia AI
GALT SEC FilingsGalectin Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET - marketscreener.com
Belapectin Phase 3 data: potential first treatment for MASH varices - Stock Titan
GALT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
GALT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Galectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALT - TipRanks
0.49%
1.47%
자본화:
|
볼륨(24시간):